Sclerostin levels in uremic patients: a link between bone and vascular disease

Abstract

Sclerostin is a marker of low-turnover bone disease in end stage renal disease patients. The aim of this study was to evaluate serum sclerostin in uremic patients, analyzing its behavior during a single hemodialysis session. Twenty-one adult patients on intermittent hemodialysis treatment were enrolled. Acetate Free Bio-filtration (AFB) was the technique employed. Uremic patients were characterized by higher levels of serum sclerostin when compared with values observed in healthy subjects. Sclerostin assessed in pre-dialysis samples was 1.4 6 1.02 ng/mL, whereas, in post dialysis samples, a reduction of sclerostin values was observed (0.8 6 0.6 ng/mL; p: 0.008). Sclerostin correlated with parameters of dialysis adequacy, such as creatinine levels and Kt/V values, and it was significantly associated with atherosclerotic disease. Receiver operating characteristics analysis revealed a good diagnostic profile in identifying atherosclerotic disease. Sclerostin, a full dialyzable substance during AFB dialysis, is closely associated with atherosclerotic disease. Its reduction obtained through AFB could represent a defensive mechanism, improving vascular disease and renal osteodystrophy. ARTICLE HISTORY

Is Sclerostin Level Associated with Cardiovascular Diseases in Hemodialysis Patients?

“…They concluded that the decrease in sclerostin level was associated with Kt/V [44]. We also observed a similar negative association between sclerostin level and Kt/V.…”

Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2–5D

“…Недавние сообщения позволяют предполагать, что высокий уровень склеростина способен отражать сниженный костный метаболизм и может быть полезным как маркер низкообменной костной болезни на продвинутых стадиях ХБП [19]. Как антагонист Wnt/β-катенин-сигнального пути, который вовлечен в биологию сосудов, склеростин может быть вовлечен в сосудистую кальцификацию [20]. Кроме того, сообщалось, что склеростин может быть ассоциирован с клиническими исходами, однако результаты противоречивы [20,21].…”

Serum sclerostin as a potential biomarker of vascular and valvular types of calcification in chronic kidney disease cases with and without maintenance hemodialysis

“…In this study, the best cutoff values obtained for serum sclerostin as a potential biomarker for both types of calcification revealed that sclerostin was more of a sensitive rather than a specific biomarker. Bruzzese et al [30] reported serum sclerostin as a reliable biomarker of VC based on a ROC curve generated cutoff value of 1.15 ng/mL (50.6 pmol/L). As regard valvular calcification, the present study to the best of our knowledge was the first to use ROC curve modality in addressing the sensitivity and the specificity of serum sclerostin as a potential biomarker of valvular calcification.…”